The UCCCC senior leadership is committed to funding protocols that have the highest potential for leading to larger scale clinical trials with the possibility of significant clinical impact and/or future external peer-reviewed funding. These studies are innovative, feasibility, or proof-of-principle studies that are deemed to be of highest priority to the Cancer Center. In the last budget period, priorities included the promotion of interdisciplinary, translational, and population research, as well as diversification of the types of trials funded by this mechanism. It is anticipated that Protocol-Specific Research (PSR) funds will support approximately 2 trials per year and will be used to fund the effort of nurses and data managers. The UCCCC issues an RFA, with specified deadlines, which is posted on the UCCCC website, distributed to Program Leaders and members of the Cancer Advisory Committee, and sent to all UCCCC members via email. The RFA outlines the application requirements, which include submission of the full study protocol, together with a one-page description of the importance and innovativeness of the study and rationale for funding, as well as a budget and budget justification. Per NCI guidelines, all studies must be investigator initiated, not otherwise funded, IRB-approved, and the budgets restricted to nursing and data management support. PSR proposals are reviewed by a committee comprised of the Director, Co-Deputy Director for Clinical Sciences, and the Associate Directors for Clinical, Basic, Translational, and Population Research. The review process takes into consideration scientific merit, innovativeness, and the likelihood that the project will lead to future large scale clinical trials or extramural funding. Funded projects are monitored on a regular basis, and accrual reports are required quarterly. If a protocol is accruing poorly, and/or it is no longer feasible to conduct the trial, the Director, in consultation with the Associate Directors, will suspend funding. Over the past 5 years, our procedures for soliciting and awarding PSR have been modified slightly. Rather than set specific submission deadlines, we have allowed for a more flexible (rolling) submission schedule to accommodate new studies opening throughout the year. In addition, protocols are first submitted to the Clinical Trials Review Committee (CTRC), and CTRC comments are provided to the reviewers. These same procedures will be employed in the next grant cycle to fund approximately two early-phase studies per year.

Public Health Relevance

The UCCCC has an extensive and strong clinical trials program. Our goal is to provide the best and most personalized treatments available as well as to develop new treatment approaches. Protocol-specific research funds provide a vehicle for supporting early-phase testing of new drugs, modalities or devices and as well as new applications of therapy.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Chicago
United States
Zip Code
Kathayat, Rahul S; Cao, Yang; Elvira, Pablo D et al. (2018) Active and dynamic mitochondrial S-depalmitoylation revealed by targeted fluorescent probes. Nat Commun 9:334
Liu, Jun; Eckert, Mark A; Harada, Bryan T et al. (2018) m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol 20:1074-1083
Bhanvadia, Raj R; VanOpstall, Calvin; Brechka, Hannah et al. (2018) MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res 24:3668-3680
Wood, Kevin; Byron, Elizabeth; Janisch, Linda et al. (2018) Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol 41:963-966
Sample, Ashley; Zhao, Baozhong; Wu, Chunli et al. (2018) The Autophagy Receptor Adaptor p62 is Up-regulated by UVA Radiation in Melanocytes and in Melanoma Cells. Photochem Photobiol 94:432-437
Hrusch, C L; Manns, S T; Bryazka, D et al. (2018) ICOS protects against mortality from acute lung injury through activation of IL-5+ ILC2s. Mucosal Immunol 11:61-70
Hope, C Matthew; Webber, Jemma L; Tokamov, Sherzod A et al. (2018) Tuned polymerization of the transcription factor Yan limits off-DNA sequestration to confer context-specific repression. Elife 7:
Wong, Gabrielle S; Zhou, Jin; Liu, Jie Bin et al. (2018) Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med 24:968-977
Wu, Chengyue; Pineda, Federico; Hormuth 2nd, David A et al. (2018) Quantitative analysis of vascular properties derived from ultrafast DCE-MRI to discriminate malignant and benign breast tumors. Magn Reson Med :
Meisel, Marlies; Hinterleitner, Reinhard; Pacis, Alain et al. (2018) Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature 557:580-584

Showing the most recent 10 out of 668 publications